Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors
暂无分享,去创建一个
W. Gaissmaier | P. Hall | D. Eccles | P. Devilee | R. Schmutzler | P. Pharoah | S. Linn | D. Stoppa-Lyonnet | S. Boccia | B. Borisch | G. Emons | A. Katalinic | C. Woopen | J. Balmaña | K. Kast | K. Rhiem | J. Gronwald | S. Moorthie | P. Dabrock | T. Spranger | S. Houwaart | J. V. van Delden | M. Van den Bulcke | S. Huster | Björn Schmitz-Luhn | P. Hall
[1] A. Antoniou,et al. Performance of breast cancer polygenic risk scores in 760 female CHEK2 germline mutation carriers. , 2020, Journal of the National Cancer Institute.
[2] A. Uitterlinden,et al. Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort , 2020, Genetics in Medicine.
[3] S. Boccia,et al. A review of the legislation of direct-to-consumer genetic testing in EU member states. , 2020, European journal of medical genetics.
[4] R. Ádány,et al. How to Integrate Personalized Medicine into Prevention? Recommendations from the Personalized Prevention of Chronic Diseases (PRECeDI) Consortium , 2019, Public Health Genomics.
[5] P. V. van Diest,et al. Supplemental MRI Screening for Women with Extremely Dense Breast Tissue. , 2019, The New England journal of medicine.
[6] Gretchen L. Gierach,et al. Toward Risk-Stratified Breast Cancer Screening: Considerations for Changes in Screening Guidelines. , 2019, JAMA oncology.
[7] H. Brenner,et al. Risk-Adapted Starting Age of Screening for Relatives of Patients With Breast Cancer. , 2019, JAMA oncology.
[8] M. Hellmich,et al. Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohort , 2019, The breast journal.
[9] Gord Glendon,et al. 10-year performance of four models of breast cancer risk: a validation study. , 2019, The Lancet. Oncology.
[10] M. García-Closas,et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors , 2019, Genetics in Medicine.
[11] Kristen S Purrington,et al. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes , 2018, American Journal of Human Genetics.
[12] S. Lönnberg,et al. The legal framework for European cervical cancer screening programmes , 2018, European journal of public health.
[13] A. Meindl,et al. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history , 2018, BMC Cancer.
[14] A. Reuss,et al. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1) , 2017, PloS one.
[15] W. Chung,et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.
[16] W. Chung,et al. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers , 2017, Journal of the National Cancer Institute.
[17] Muin J Khoury,et al. A knowledge base for tracking the impact of genomics on population health , 2016, Genetics in Medicine.
[18] Muin J Khoury,et al. Convergence of Implementation Science, Precision Medicine, and the Learning Health Care System: A New Model for Biomedical Research. , 2016, JAMA.
[19] I. Slade,et al. Preparing clinicians for genomic medicine , 2016, Postgraduate Medical Journal.
[20] Zicheng Xu,et al. Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review , 2016, Clinical Cancer Research.
[21] T. Pang,et al. Evidence for Health III: Making evidence-informed decisions that integrate values and context , 2016, Health Research Policy and Systems.
[22] Tanja Fehm,et al. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer , 2016, Journal of Medical Genetics.
[23] G. Parmigiani,et al. Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. , 2016, JAMA.
[24] M. Khoury,et al. Targeted Cancer Screening in Average-Risk Individuals. , 2015, American journal of preventive medicine.
[25] H. D. de Koning,et al. Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC) , 2015, International journal of cancer.
[26] Nazneen Rahman,et al. Gene-panel sequencing and the prediction of breast-cancer risk. , 2015, The New England journal of medicine.
[27] P. Pharoah,et al. Do Health Professionals Need Additional Competencies for Stratified Cancer Prevention Based on Genetic Risk Profiling? , 2015, Journal of personalized medicine.
[28] C. Marchetti,et al. Bilateral Risk-Reduction Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Meta-analysis , 2015, Annals of Surgical Oncology.
[29] M. Khoury,et al. Opportunities for Translational Epidemiology: The Important Role of Observational Studies to Advance Precision Oncology , 2015, Cancer Epidemiology, Biomarkers & Prevention.
[30] M. Khoury,et al. What is translational genomics? An expanded research agenda for improving individual and population health , 2014, Applied & translational genomics.
[31] R. Busse,et al. The new regulation to investigate potentially beneficial diagnostic and therapeutic methods in Germany: up to international standard? , 2014, Health policy.
[32] M. Khoury,et al. Utility before business , 2014, Genetics in Medicine.
[33] R. Tollenaar,et al. Improved overall survival after contralateral risk‐reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis , 2014, International journal of cancer.
[34] H. Burton,et al. Personalised medicine in the UK: challenges of implementation and impact on healthcare system , 2014, Genome Medicine.
[35] Wylie Burke,et al. Genetic Tests: Clinical Validity and Clinical Utility , 2014, Current protocols in human genetics.
[36] M. Leach,et al. MRI breast screening in high-risk women: cancer detection and survival analysis , 2014, Breast Cancer Research and Treatment.
[37] Paul K. J. Han,et al. Presenting quantitative information about decision outcomes: a risk communication primer for patient decision aid developers , 2013, BMC Medical Informatics and Decision Making.
[38] E. Birney,et al. Policy challenges of clinical genome sequencing , 2013, BMJ.
[39] P. Pharoah,et al. Public health genomics and personalized prevention: lessons from the COGS project , 2013, Journal of internal medicine.
[40] P. Pharoah,et al. Implementing risk-stratified screening for common cancers: a review of potential ethical, legal and social issues , 2013, Journal of public health.
[41] P. Pharoah,et al. Public health implications from COGS and potential for risk stratification and screening , 2013, Nature Genetics.
[42] G. Elwyn,et al. Personalised risk communication for informed decision making about taking screening tests. , 2013, The Cochrane database of systematic reviews.
[43] P. Hall,et al. Incorporating genomics into breast and prostate cancer screening: assessing the implications , 2013, Genetics in Medicine.
[44] A. Cecile J.W. Janssens,et al. How can polygenic inheritance be used in population screening for common diseases? , 2013, Genetics in Medicine.
[45] R. Eeles,et al. Stratified Cancer Screening: The Practicalities of Implementation , 2013, Public Health Genomics.
[46] A. Brand,et al. European Best Practice Guidelines for Quality Assurance, Provision and Use of Genome-based Information and Technologies: the 2012 Declaration of Rome , 2012, Drug metabolism and drug interactions.
[47] W. Gaissmaier,et al. Numbers can be worth a thousand pictures: individual differences in understanding graphical and numerical representations of health-related information. , 2012, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.
[48] Julie O. Culver,et al. Essential Elements of Genetic Cancer Risk Assessment, Counseling, and Testing: Updated Recommendations of the National Society of Genetic Counselors , 2012, Journal of Genetic Counseling.
[49] S. Athar. Principles of Biomedical Ethics , 2011, The Journal of IMA.
[50] Edward T. Cokely,et al. Effective communication of risks to young adults: using message framing and visual aids to increase condom use and STD screening. , 2011, Journal of experimental psychology. Applied.
[51] M. Galesic,et al. Corrigendum to: "Who profits from visual aids: Overcoming challenges in people's understanding of risks" [Social Science & Medicine, 70 (2010), 1019-1025. , 2010, Social science & medicine.
[52] Gerd Gigerenzer,et al. Do Icon Arrays Help Reduce Denominator Neglect? , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.
[53] Heather Skirton,et al. Genetic education and the challenge of genomic medicine: development of core competences to support preparation of health professionals in Europe , 2010, European Journal of Human Genetics.
[54] A. Andermann,et al. Genetic Screening: A Conceptual Framework for Programmes and Policy-Making , 2010, Journal of health services research & policy.
[55] M. Galesic,et al. Who profits from visual aids: overcoming challenges in people's understanding of risks [corrected]. , 2010, Social science & medicine.
[56] M. Galesic,et al. Statistical Numeracy for Health A Cross-cultural Comparison With Probabilistic National Samples , 2010 .
[57] A. Andermann,et al. Guiding Policy Decisions for Genetic Screening: Developing a Systematic and Transparent Approach , 2009, Public Health Genomics.
[58] Steven Woloshin,et al. Using a Drug Facts Box to Communicate Drug Benefits and Harms Two Randomized Trials , 2009, Annals of Internal Medicine.
[59] A. Andermann,et al. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. , 2008, Bulletin of the World Health Organization.
[60] J Dundon,et al. Interventions to improve risk communication in clinical genetics: systematic review. , 2008, Patient education and counseling.
[61] Lisa M. Schwartz,et al. PSYCHOLOGICAL SCIENCE IN THE PUBLIC INTEREST Helping Doctors and Patients Make Sense of Health Statistics , 2022 .
[62] S. Narod. Modifiers of risk of hereditary breast cancer , 2006, Oncogene.
[63] P. Ubel,et al. Reducing the Influence of Anecdotal Reasoning on People’s Health Care Decisions: Is a Picture Worth a Thousand Statistics? , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.
[64] J. Kaprio,et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.
[65] Nancy L. Kocovski,et al. Perception of Quantitative Information for Treatment Decisions , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.
[66] G. Gigerenzer,et al. The Barrier to Informed Choice in Cancer Screening: Statistical Illiteracy in Physicians and Patients. , 2018, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[67] P. Pharoah,et al. Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model , 2018 .
[68] REGULATION (EU) 2019/518 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL , 2015 .
[69] Additional protocol to the convention on human rights and biomedicine, concerning genetic testing for health purposes. , 2008, Revista de derecho y genoma humano = Law and the human genome review.
[70] Ja Wilson,et al. Principles and practice of screening for disease , 1968 .